Dana Messinger
YOU?
Author Swipe
View article: CNSC-85. TARGETING USP1 POTENTIATES RADIOSENSITIVITY IN H3K27M-MUTANT DMG BY DISRUPTING CELL CYCLE CHECKPOINTS AND DNA REPAIR MECHANISMS
CNSC-85. TARGETING USP1 POTENTIATES RADIOSENSITIVITY IN H3K27M-MUTANT DMG BY DISRUPTING CELL CYCLE CHECKPOINTS AND DNA REPAIR MECHANISMS Open
Diffuse midline gliomas (DMGs) are universally lethal pediatric brain tumors characterized by H3K27M mutations in H3F3A or H3C2. Current treatments are limited, with radiotherapy offering only transient benefit and a median survival of jus…
View article: EXTH-107. Effective targeting of EGFR-driven diffuse midline glioma with BLU5082, a novel brain-penetrant EGFR-targeting tyrosine kinase inhibitor (TKI)
EXTH-107. Effective targeting of EGFR-driven diffuse midline glioma with BLU5082, a novel brain-penetrant EGFR-targeting tyrosine kinase inhibitor (TKI) Open
Diffuse midline gliomas (DMGs) are lethal pediatric high-grade brain tumors with a prognosis of less than two years from diagnosis, the majority of which harbor the H3K27M histone mutation. A subgroup of DMGs harbor alterations in epiderma…
View article: CSIG-28. ATRX LOSS LEADS TO H3K4ME3-DRIVEN EPIGENETIC DYSREGULATION OF OLIGODENDROCYTE DIFFERENTIATION AND CELL CYCLE CONTROL IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG)
CSIG-28. ATRX LOSS LEADS TO H3K4ME3-DRIVEN EPIGENETIC DYSREGULATION OF OLIGODENDROCYTE DIFFERENTIATION AND CELL CYCLE CONTROL IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA (DMG) Open
Diffuse midline gliomas (DMGs) are lethal pediatric cancers. Histone H3.3 (H3-3A) is the most commonly mutated gene in DMG; up to 80% exhibit a gain-of-function mutation at lysine 27 (K27M). K27M mutations often co-occur with loss of ATRX,…
View article: Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Correction: Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
View article: Table S15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
GSEA analysis of genes with significantly increased H3K27me3 in ONC201-treated versus untreated patients.
View article: Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S3 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Individual cases from historical control datasets.
View article: Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Individual patients with H3K27M-mutant DMG treated with ONC201.
View article: Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S11 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S13 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
GSEA analysis of genes with significantly lower chromatin accessibility at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S12 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S12 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Results of pathway impact analysis after performing integrated RNA-seq and metabolomics analysis using MetaboAnalyst.
View article: Table S1 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S1 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Baseline characteristics of ONC201-treated H3K27M-DMG patients included in analysis.
View article: Table S6 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S6 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Radiographic response versus gene expression Spearman's correlation coefficient for all protein-coding genes.
View article: Table S7 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S7 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
View article: Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S16 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
ONC201 dosage chart for patients younger than 18 years of age.
View article: Supplementary Data S1 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Supplementary Data S1 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Protocol for NCT03416530, ONC201-014: ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3K27M Gliomas.
View article: Supplementary Data S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Supplementary Data S2 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Protocol for NCT03134131, ONC201-018: Expanded Access to ONC201 for Patients with H3K27M-mutant and/or Midline High Grade Gliomas.
View article: Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S10 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S9 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S9 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Upregulated and downregulated genes in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S8 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
View article: Table S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S5 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
VST-transformed gene expression values for all samples and protein-coding genes.
View article: Table S14 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S14 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
GSEA analysis of genes with significantly lower H3K27ac at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
View article: Supplementary Figures 1-15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Supplementary Figures 1-15 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends.Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG.Fig. S2. Progression-free sur…
View article: Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways
Table S4 from Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways Open
Summary of historical control datasets.
View article: Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
Baseline characteristics of ONC201-treated H3K27M-DMG patients included in analysis.
View article: Table S5 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Table S5 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
VST-transformed gene expression values for all samples and protein-coding genes.
View article: Data from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Data from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
H3K27M-mutant diffuse midline glioma (DMG) patients have no proven effective therapies. ONC201 has recently demonstrated efficacy in these patients, but the mechanism behind this remains unknown. We assessed clinical outcomes, tumor sequen…
View article: Table S7 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Table S7 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
View article: Table S11 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Table S11 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
Volcano plot of differentially expressed genes in DIPG007 cells treated with ONC201 versus vehicle.
View article: Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Table S1 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
Baseline characteristics of ONC201-treated H3K27M-DMG patients included in analysis.
View article: Supplementary Figures 1-15 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Supplementary Figures 1-15 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways Open
Contains supplementary data and table titles and as well as supplementary figures with associated titles and legends. Fig. S1. Selection method for planned efficacy analysis of ONC201 in patients with H3K27MDMG. Fig. S2. Progression-free s…